|
|
Abstract
Mortality and loss to follow-up in an antiretroviral therapy (ART) program in urban Cameroon
Tsague L.1, Koulla S.2, Kenfak A.3, Abong T.4, Mapoure Y.5, Tejiokem M.6, Kouanfack C.4, Mbangue M.5, Mosoko J.2, Pouillot R.6, Bella L.7
Objectives: To understanding the determinants of death and losses to follow-up (LFU) among patients receiving antiretroviral therapy (ART) in Cameroon.
Methods: We reviewed existing clinical records from indigent patients enrolled on ARV at two urban hospitals in Cameroon. We used an extended Cox’s model to compute adjusted hazard ratios (aHR) of death and losses to follow-up.
Results: Of 455 patients, 314 (69•5%) were women, median (IQR) age and baseline CD4 count were respectively 36 years (30 – 43) and 110 cells/µL (39 – 177). Forty patients (9%) had active tuberculosis at enrollment. After a median (IQR) follow-up of 18 months (10–18), 346 (76%) were still in care, 8 (1•8%) were known dead, and 101 (22•2%) were LFU. Seven out of eight deaths occurred within 7 months on ART therapy. Mortality rate was 1•5 per100 person-years. Severe baseline immunosuppression (aHR 2∙3; 95% CI 1∙4 - 3∙7) and active tuberculosis (aHR 1∙8; 95% CI 1∙0 - 3∙6) were independent predictors of losses to follow-up during the first 6 months on therapy.
Conclusions: To ensure and sustain beneficial effects of ART, innovative strategies should be designed to ensure early identification and recruitment of patients before severe immunosuppression.
4th IAS Conference on HIV Pathogenesis, Treatment and Prevention
Abstract no.
CDB026
Suggested Citation
"TsagueL., et al.
Mortality and loss to follow-up in an antiretroviral therapy (ART) program in urban Cameroon.
:
4th IAS Conference on HIV Pathogenesis, Treatment and Prevention:
Abstract no.
CDB026"
|
|
|